Lophius Biosciences
Regensburg
About Lophius Biosciences
Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area of Immunology and T-cell diagnostics. Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.4M
- Funding stage: Late Stage Venture
- Last round: Series H (Mar 2017)
- Website: lophius.com
- Phone: 49 491 94 44 637
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/lophius-biosciences-113967 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.